Briefs

Pfizer expands use of NLP-based knowledge discovery platform, Linguamatics I2E, for text mining across R&D

(16 April 2008, Cambridge, UK) Linguamatics Ltd, a leader in natural language processing (NLP) for the life science market, today announced that Pfizer has extended its strategic collaboration with Linguamatics to use the I2E knowledge discovery platform for text mining across their R&D organization. Pfizer researchers and other decision-makers will use I2E to discover and extract key facts and relationships from internal and external literature sources to support decision-making. Financial details of the agreement were not disclosed.

"High performance text mining is strategically important for any global pharma company, and especially a market leader like Pfizer," said Giles Day, Senior Director of R&D Informatics, Pfizer. "Our expanded collaboration with Linguamatics underlines our commitment to exploit the value of intelligence from text within our R&D operations. For example, the use of I2E supports our DKTP (Deep Knowledge of Targets and Pathways) strategy to find novel relationships between diseases and targets for rapid identification of therapeutically relevant targets."

For further information on Linguamatics products and solutions, visit www.linguamatics.com.